TCR2 Therapeutics Inc. (NASDAQ:TCRR) concluded the trading at $2.62 on Friday, June 10, with a fall of -3.32% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $2.71 and 5Y monthly beta was reading 2.20 with its price kept floating in the range of $2.48 and $2.66 on the day. Considering stock’s 52-week price range provides that TCRR hit a high price of $19.03 and saw its price falling to a low level of $2.07 during that period. Over a period of past 1-month, stock came adding 20.74% in its value.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
With its current market valuation of $98.49 million, TCR2 Therapeutics Inc. is set to declare its quarterly results on Mar 09, 2022 – Mar 14, 2022. Analysts are in estimates of -$0.79 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$3.03 for 2022 with estimates of that growing to -$2.67 in next year. These estimates are suggesting current year growth of -15.20% for EPS and 11.90% growth next year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review TCRR stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 100% Sell for it.
According to ratings assigned by 9 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 3 of them are recommending TCR2 Therapeutics Inc. (TCRR) as a Hold, while 6 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the TCRR stock which is currently positioned at 0. It further provides that stock’s current price level is 10.57% away from its 20-day simple moving average and is 8.57% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 58.16 while volatility remained at 8.31% over the past week which changes to 7.22% when measuring it over the past month. Beta is valued at 2.20, while measure of average true range or ATR is currently at 0.19. In predicting price targets of as low as $2.00 and as high as $29.00, analysts are in agreement on assigning the stock over the next 12 months average price target of $13.89. Stock’s current price level is 23.66% above from estimated low price target while it is -1006.87% below the estimated high; and even if the TCRR’s share succeeded to reach the median price of $15.00, then the outlook of -472.52% could come to the excitement of the investors.
Having a second look at TCR2 Therapeutics Inc. (NASDAQ:TCRR) provides that stock’s average daily trading volume for 3 months was 448.17K. Number of outstanding shares of the stock stood at 38.51 million.
The percentage of outstanding shares held by the insiders is 0.80% while it is 75.50% for the institutional holders. Subtraction of -43.78% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.